Cargando…

Carvacrol Attenuates Diabetic Cardiomyopathy by Modulating the PI3K/AKT/GLUT4 Pathway in Diabetic Mice

Background: Diabetic cardiomyopathy (DCM), a common complication of diabetes mellitus, eventually leads to heart failure. Carvacrol is a food additive with diverse bioactivities. We aimed to study the protective effects and mechanisms of carvacrol in DCM. Methods: We used a streptozotocin-induced an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Ning, Mai, Yunpei, Qiu, Xiaoxia, Yuan, Wenchang, Li, Yilang, Luo, Chengfeng, Liu, Yun, Zhang, Guiping, Zhao, Ganjiang, Luo, Jian-dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751321/
https://www.ncbi.nlm.nih.gov/pubmed/31572181
http://dx.doi.org/10.3389/fphar.2019.00998
_version_ 1783452599966498816
author Hou, Ning
Mai, Yunpei
Qiu, Xiaoxia
Yuan, Wenchang
Li, Yilang
Luo, Chengfeng
Liu, Yun
Zhang, Guiping
Zhao, Ganjiang
Luo, Jian-dong
author_facet Hou, Ning
Mai, Yunpei
Qiu, Xiaoxia
Yuan, Wenchang
Li, Yilang
Luo, Chengfeng
Liu, Yun
Zhang, Guiping
Zhao, Ganjiang
Luo, Jian-dong
author_sort Hou, Ning
collection PubMed
description Background: Diabetic cardiomyopathy (DCM), a common complication of diabetes mellitus, eventually leads to heart failure. Carvacrol is a food additive with diverse bioactivities. We aimed to study the protective effects and mechanisms of carvacrol in DCM. Methods: We used a streptozotocin-induced and db/db mouse model of types 1 and 2 diabetes mellitus (T1DM and T2DM), respectively. Both study groups received daily intraperitoneal injections of carvacrol for 6 weeks. Cardiac remodeling was evaluated by histological analysis. We determined gene expression of cardiac remodeling markers (Nppa and Myh7) by quantitative real-time PCR and cardiac function by echocardiography. Changes of PI3K/AKT signaling were determined with Western blotting. GLUT4 translocation was evaluated by Western blotting and immunofluorescence staining. Results: Compared with control mice, both T1DM and T2DM mice showed cardiac remodeling and left ventricular dysfunction. Carvacrol significantly reduced blood glucose levels and suppressed cardiac remodeling in mice with T1DM and T2DM. At the end of the treatment period, both T1DM and T2DM mice showed lesser cardiac hypertrophy, Nppa and Myh7 mRNA expressions, and cardiac fibrosis, compared to mice administered only the vehicle. Moreover, carvacrol significantly restored PI3K/AKT signaling, which was impaired in mice with T1DM and T2DM. Carvacrol increased levels of phosphorylated PI3K, PDK1, AKT, and AS160 and inhibited PTEN phosphorylation in mice with T1DM and T2DM. Carvacrol treatment promoted GLUT4 membrane translocation in mice with T1DM and T2DM. Metformin was used as the positive drug control in T2DM mice, and carvacrol showed comparable effects to that of metformin on cardiac remodeling and modulation of signaling pathways. Conclusion: Carvacrol protected against DCM in mice with T1DM and T2DM by restoring PI3K/AKT signaling-mediated GLUT4 membrane translocation and is a potential treatment of DCM.
format Online
Article
Text
id pubmed-6751321
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67513212019-09-30 Carvacrol Attenuates Diabetic Cardiomyopathy by Modulating the PI3K/AKT/GLUT4 Pathway in Diabetic Mice Hou, Ning Mai, Yunpei Qiu, Xiaoxia Yuan, Wenchang Li, Yilang Luo, Chengfeng Liu, Yun Zhang, Guiping Zhao, Ganjiang Luo, Jian-dong Front Pharmacol Pharmacology Background: Diabetic cardiomyopathy (DCM), a common complication of diabetes mellitus, eventually leads to heart failure. Carvacrol is a food additive with diverse bioactivities. We aimed to study the protective effects and mechanisms of carvacrol in DCM. Methods: We used a streptozotocin-induced and db/db mouse model of types 1 and 2 diabetes mellitus (T1DM and T2DM), respectively. Both study groups received daily intraperitoneal injections of carvacrol for 6 weeks. Cardiac remodeling was evaluated by histological analysis. We determined gene expression of cardiac remodeling markers (Nppa and Myh7) by quantitative real-time PCR and cardiac function by echocardiography. Changes of PI3K/AKT signaling were determined with Western blotting. GLUT4 translocation was evaluated by Western blotting and immunofluorescence staining. Results: Compared with control mice, both T1DM and T2DM mice showed cardiac remodeling and left ventricular dysfunction. Carvacrol significantly reduced blood glucose levels and suppressed cardiac remodeling in mice with T1DM and T2DM. At the end of the treatment period, both T1DM and T2DM mice showed lesser cardiac hypertrophy, Nppa and Myh7 mRNA expressions, and cardiac fibrosis, compared to mice administered only the vehicle. Moreover, carvacrol significantly restored PI3K/AKT signaling, which was impaired in mice with T1DM and T2DM. Carvacrol increased levels of phosphorylated PI3K, PDK1, AKT, and AS160 and inhibited PTEN phosphorylation in mice with T1DM and T2DM. Carvacrol treatment promoted GLUT4 membrane translocation in mice with T1DM and T2DM. Metformin was used as the positive drug control in T2DM mice, and carvacrol showed comparable effects to that of metformin on cardiac remodeling and modulation of signaling pathways. Conclusion: Carvacrol protected against DCM in mice with T1DM and T2DM by restoring PI3K/AKT signaling-mediated GLUT4 membrane translocation and is a potential treatment of DCM. Frontiers Media S.A. 2019-09-12 /pmc/articles/PMC6751321/ /pubmed/31572181 http://dx.doi.org/10.3389/fphar.2019.00998 Text en Copyright © 2019 Hou, Mai, Qiu, Yuan, Li, Luo, Liu, Zhang, Zhao and Luo http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Hou, Ning
Mai, Yunpei
Qiu, Xiaoxia
Yuan, Wenchang
Li, Yilang
Luo, Chengfeng
Liu, Yun
Zhang, Guiping
Zhao, Ganjiang
Luo, Jian-dong
Carvacrol Attenuates Diabetic Cardiomyopathy by Modulating the PI3K/AKT/GLUT4 Pathway in Diabetic Mice
title Carvacrol Attenuates Diabetic Cardiomyopathy by Modulating the PI3K/AKT/GLUT4 Pathway in Diabetic Mice
title_full Carvacrol Attenuates Diabetic Cardiomyopathy by Modulating the PI3K/AKT/GLUT4 Pathway in Diabetic Mice
title_fullStr Carvacrol Attenuates Diabetic Cardiomyopathy by Modulating the PI3K/AKT/GLUT4 Pathway in Diabetic Mice
title_full_unstemmed Carvacrol Attenuates Diabetic Cardiomyopathy by Modulating the PI3K/AKT/GLUT4 Pathway in Diabetic Mice
title_short Carvacrol Attenuates Diabetic Cardiomyopathy by Modulating the PI3K/AKT/GLUT4 Pathway in Diabetic Mice
title_sort carvacrol attenuates diabetic cardiomyopathy by modulating the pi3k/akt/glut4 pathway in diabetic mice
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751321/
https://www.ncbi.nlm.nih.gov/pubmed/31572181
http://dx.doi.org/10.3389/fphar.2019.00998
work_keys_str_mv AT houning carvacrolattenuatesdiabeticcardiomyopathybymodulatingthepi3kaktglut4pathwayindiabeticmice
AT maiyunpei carvacrolattenuatesdiabeticcardiomyopathybymodulatingthepi3kaktglut4pathwayindiabeticmice
AT qiuxiaoxia carvacrolattenuatesdiabeticcardiomyopathybymodulatingthepi3kaktglut4pathwayindiabeticmice
AT yuanwenchang carvacrolattenuatesdiabeticcardiomyopathybymodulatingthepi3kaktglut4pathwayindiabeticmice
AT liyilang carvacrolattenuatesdiabeticcardiomyopathybymodulatingthepi3kaktglut4pathwayindiabeticmice
AT luochengfeng carvacrolattenuatesdiabeticcardiomyopathybymodulatingthepi3kaktglut4pathwayindiabeticmice
AT liuyun carvacrolattenuatesdiabeticcardiomyopathybymodulatingthepi3kaktglut4pathwayindiabeticmice
AT zhangguiping carvacrolattenuatesdiabeticcardiomyopathybymodulatingthepi3kaktglut4pathwayindiabeticmice
AT zhaoganjiang carvacrolattenuatesdiabeticcardiomyopathybymodulatingthepi3kaktglut4pathwayindiabeticmice
AT luojiandong carvacrolattenuatesdiabeticcardiomyopathybymodulatingthepi3kaktglut4pathwayindiabeticmice